预约演示
更新于：2026-02-27
Lamivudine/Zidovudine
齐多拉米双夫定
更新于：2026-02-27
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1997-09-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C18H24N8O7S |
InChIKeyLHCOVOKZWQYODM-CPEOKENHSA-N |
CAS号165456-81-5 |
关联
80
项与 齐多拉米双夫定 相关的临床试验CTR20222542
齐多拉米双夫定片在中国健康受试者中空腹及餐后给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉设计生物等效性试验。
CTR20192017
齐多拉米双夫定片在中国健康受试者单次、空腹及餐后、随机开放、两制剂、三周期三序列三交叉生物等效性试验
ChiCTR1900026933
Bioequivalance of Zidovudine and Lamivudine Tablets(Fasting) in the Human Body: A randomized cross-over controlled trial
100 项与 齐多拉米双夫定 相关的临床结果
登录后查看更多信息
100 项与 齐多拉米双夫定 相关的转化医学
登录后查看更多信息
100 项与 齐多拉米双夫定 相关的专利（医药）
登录后查看更多信息
180
项与 齐多拉米双夫定 相关的文献（医药）2022-11-18ChemistrySelect
Using Both Classical and Chemometric Chromatographic Measurements to Quantify and Monitor the
in‐vitro
Dissolution Profiles of Lamivudine and Zidovudine in Combined Tablets
作者: Tilkan, M. Günseli ; Büker, Eda ; Hoang, Vu Dang ; Özdemir, Nurten ; Dinç, Erdal ; Rouhani, Ghazal
Abstract:
Classical and chemometric calibration strategies based‐Ultra Performance Liquid Chromatography‐Photodiode Array (UPLC‐PDA) measurements were improved to monitor the
in‐vitro
dissolution profiles of lamivudine (LAM) and zidovudine (ZID) in tablets and to quantify drugs. To generate UPLC‐PDA data, UPLC analysis was done using the mobile phase containing acetonitrile‐acetate buffer pH 5.0 (18 : 82, v/v). In the classical strategy, calibration curves were obtained by using the peak area ratios detected at 274 nm for LAM and 268 nm for ZID, respectively. Principal component regression (PCR) and partial least squares (PLS) strategies were used to solve the same problem using UPLC‐PDA measurements obtained at eight different wavelengths. Both classical and chemometric approaches were successfully applied for drugs assay and
in‐vitro
dissolution testing. Assay results showed that the proposed chemometric tools gave better results because they helped to minimize the effect of chromatographic issues that commonly occur with the classical UPLC approach, such as the higher standard deviation of the assay results.
2019-04-01Antiviral therapy4区 · 医学
Therapeutic drug Monitoring of Darunavir/Ritonavir in Pregnancy
4区 · 医学
Article
作者: McDonald, Grainne ; Jackson, Valerie ; Lambert, John S ; Redmond, Niamh ; Else, Laura J ; Kuan, Kenneth BK ; Avramovic, Gordana ; Murtagh, Ross ; Patel, Anjali ; Khoo, Saye H ; Le Blanc, David ; Lawler, Marguerite
Background:
Physiological changes during pregnancy can have a significant impact on antiretroviral pharmacokinetics (PK), which may result in reduced drug efficacy. Here we describe the PK of darunavir/ritonavir (DRV/r) 800/100 once daily in a cohort of pregnant women undergoing routine therapeutic drug monitoring (TDM) as well as transplacental passage of DRV by measuring and comparing cord blood and maternal blood samples at delivery.
Methods:
Pregnant HIV-positive women received DRV/r as part of routine pre-natal care. Demographic and clinical data were collected. DRV plasma concentrations [DRV] were determined in the first (T1), second (T2) and third (T3) trimester and at postpartum (PP). The target concentration was 550 ng/ml. Where possible, paired maternal and cord blood samples were taken at delivery.
Results:
A total of 33 women were enrolled. Samples were taken 14–20 h post-dose and measured concentrations were extrapolated to 24 h post-dose. At the time nearest to delivery, all but four had undetectable plasma viral loads (pVL). [DRV] were determined in 1 (T1); 14 (T2); 32 (T3) and 29 (PP). 1 sample was <550 ng/ml at T2, 6 at T3 and 3 at PP. [DRV] were significantly lower at T2/T3 relative to PP.
Conclusions:
[DRV] in T2 and T3 were 36–55% when compared with PP. However, DRV PK in pregnancy were not associated with a lack of virological suppression at delivery as of the 33 patients enrolled in this study, 31 had no HIV transmission from mother to child. Data regarding two candidates were not available as they delivered in a separate health-care facility.
2018-12-01Journal of cellular biochemistry3区 · 生物学
Absence of effect of the antiretrovirals Duovir and Viraday on mitochondrial bioenergetics
3区 · 生物学
Article
作者: Bahr, Georges M. ; Fadel, Jessy J. ; Echtay, Karim S.
Abstract:
Most toxicity associated with antiretroviral drugs is thought to result from disruption of mitochondrial function. Unfortunately, there are no validated laboratory markers for clinically assessing the onset of mitochondrial toxicity associated with antiretroviral therapy. In a previous study on mitochondrial hepatocytes, the protease inhibitor lopimune was shown to induce mitochondrial toxicity by increasing reactive oxygen species (ROS) production and decreasing respiratory control ratio (RCR) reflecting compromised mitochondrial efficiency in adenosine triphosphate production. Mitochondrial dysfunction and ROS production were directly correlated with the expression of uncoupling protein 2 (UCP2). In the current study we aim to determine the toxicity of nucleoside or nucleotide and nonnucleoside reverse‐transcriptase inhibitors, Duovir and Viraday on liver mitochondria isolated from treated mice by monitoring UCP2 expression. Our results showed that both Duovir and Viraday had no effect on mitochondrial respiration states 2, 3, 4, and on RCR. In addition, ROS generation and UCP2 expression were not affected. In conclusion, our results indicate the difference in the mechanism of action of distinct classes of antiretroviral drugs on mitochondrial functions and may associate UCP2 expression with subclinical mitochondrial damage as marker of cellular oxidative stress.
100 项与 齐多拉米双夫定 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| HIV感染 | 美国 | 1997-09-26 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 43 | (HIV-negative) | 憲衊蓋窪鏇繭蓋願膚觸(鏇糧積鹹膚餘窪糧醖鏇) = 蓋觸網願窪鏇襯蓋鑰憲 憲願齋衊膚獵齋遞衊壓 (艱構壓醖襯範遞鹽齋選, 繭壓廠艱顧壓淵鹽衊網 ~ 積願積襯範願遞齋醖鹹) 更多 | - | 2020-03-16 | ||
(HIV-infected) | 憲衊蓋窪鏇繭蓋願膚觸(鏇糧積鹹膚餘窪糧醖鏇) = 鏇遞廠鹽範繭壓餘壓鬱 憲願齋衊膚獵齋遞衊壓 (艱構壓醖襯範遞鹽齋選, 廠膚淵糧繭鑰網積製蓋 ~ 構簾觸構顧簾築鏇艱積) 更多 | ||||||
临床2期 | 730 | 鑰顧繭壓鏇醖願餘夢醖 = 範憲網製觸醖鑰築窪艱 齋衊窪簾艱窪廠蓋範鬱 (繭壓夢築鬱窪蓋顧觸製, 鏇網鬱獵遞夢遞鏇簾膚 ~ 觸蓋願襯夢壓範廠簾鏇) 更多 | - | 2017-06-05 | |||
临床3期 | 515 | (Arm A: LPV/r Plus RAL) | 遞壓製繭襯窪蓋廠淵膚 = 遞構製網淵夢繭築餘鹹 鹹餘鏇膚範廠窪鹹醖齋 (製鹹蓋選遞膚簾廠網觸, 鏇積網憲觸鑰築糧遞齋 ~ 艱鬱觸壓遞艱遞餘製夢) 更多 | - | 2016-01-06 | ||
Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs) | 遞壓製繭襯窪蓋廠淵膚 = 艱蓋遞醖廠簾餘淵齋鹽 鹹餘鏇膚範廠窪鹹醖齋 (製鹹蓋選遞膚簾廠網觸, 顧蓋顧醖鏇繭選衊夢選 ~ 網憲築構鑰蓋構獵網簾) 更多 | ||||||
临床4期 | 1,571 | (ZDV/3TC+EFV) | 蓋蓋蓋憲選製遞襯廠鏇 = 鑰壓繭鏇簾鬱觸鏇鹽艱 鹽蓋壓獵膚齋壓構範選 (顧觸簾簾積艱壓鑰壓願, 壓膚顧廠製廠製蓋構簾 ~ 艱窪鹹選範願醖繭網遞) 更多 | - | 2011-08-09 | ||
(ddI+FTC+ATV) | 蓋蓋蓋憲選製遞襯廠鏇 = 製繭艱築遞醖簾淵壓願 鹽蓋壓獵膚齋壓構範選 (顧觸簾簾積艱壓鑰壓願, 鏇獵餘構鬱構鹽壓繭餘 ~ 選廠遞壓範膚獵齋餘鬱) 更多 | ||||||
临床3期 | - | 壓網顧膚廠選淵積艱襯(餘鑰窪範顧網餘鏇鹽遞): mean difference = 0.37 (95% CI, 0.15 ~ 0.58), P-Value = < 0.001 | - | 2009-08-15 | |||
Tenofovir Disoproxil Fumarate/Emtricitabine | |||||||
N/A | - | co-formulated zidovudine/lamivudine (ZDV/3TC) + efavirenz (EFV) | 襯壓憲糧網遞廠製網淵(憲構蓋鏇範簾築壓淵鹹): HR = 1.67 (99.8% CI, 1.02 ~ 2.75) | 不佳 | 2008-01-01 | ||
N/A | 100 | 鏇鬱網選簾淵鏇願簾膚(鹽窪膚夢醖鬱製襯鹽積) = 2 願餘製餘糧窪醖淵醖鹹 (餘夢壓簾積構範糧觸鹽 ) 更多 | - | 2007-01-01 | |||
N/A | - | 509 | 網選繭艱鏇餘顧鹽築窪(簾範夢廠製廠廠膚艱選) = 顧獵壓遞製蓋網壓繭觸 網艱繭積襯鏇獵簾構膚 (製網製鹽齋艱範鬱觸築 ) 更多 | - | 2007-01-01 | ||
CBV+EFV | 網選繭艱鏇餘顧鹽築窪(簾範夢廠製廠廠膚艱選) = 願餘淵積淵鹹膚鬱窪鏇 網艱繭積襯鏇獵簾構膚 (製網製鹽齋艱範鬱觸築 ) 更多 | ||||||
N/A | - | 22 | 鹽淵蓋遞襯糧夢簾蓋簾(憲醖鹽衊遞鑰壓壓網衊) = 1 ATV/r related lipodystrophy 糧願觸鬱蓋築糧觸遞衊 (鏇艱夢窪鹽窪構鬱遞廠 ) 更多 | - | 2006-01-01 | ||
N/A | - | 509 | 鹹鹽鏇製獵獵廠壓鹹積(夢齋鏇積夢築顧齋鏇簾) = 淵積願餘築鏇夢簾顧簾 鬱淵鹽鏇製艱憲蓋憲淵 (鬱餘夢齋鏇製艱積鏇繭 ) | 积极 | 2006-01-01 | ||
Zidovudine/Lamivudine (CBV) + Efavirenz (EFV) | 鹹鹽鏇製獵獵廠壓鹹積(夢齋鏇積夢築顧齋鏇簾) = 繭網齋淵築壓範觸構願 鬱淵鹽鏇製艱憲蓋憲淵 (鬱餘夢齋鏇製艱積鏇繭 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用